What is it about?
this is a review of safety considerations of available and investigational drugs or biological therapies that are available for CMV management and treatment.
Featured Image
Photo by camilo jimenez on Unsplash
Why is it important?
with the advance in CMV knowledge and therapies, it is good to keep track about the drawback (not only the strong points) of our available therapeutics.
Perspectives
Read the Original
This page is a summary of: Safety considerations with current and emerging antiviral therapies for cytomegalovirus infection in transplantation, Expert Opinion on Drug Safety, September 2019, Taylor & Francis,
DOI: 10.1080/14740338.2019.1662787.
You can read the full text:
Contributors
The following have contributed to this page